洛铂与顺铂分别联合放疗对局部晚期宫颈癌的疗效和安全性比较

Efficacy and safety of lobaplatin combined with radiotherapy versus cisplatin plus radiotherapy for locally advanced cervical cancer

目的比较洛铂与顺铂分别联合放疗对局部晚期宫颈癌患者的疗效和安全性。方法筛选100例国际妇产科联盟(FIGO)分期为ⅡB期的宫颈癌患者作为研究对象,根据使用铂类药物的不同分为洛铂组和顺铂组,每组50例。洛铂组放疗期间接受洛铂10 mg/m^(2)静脉注射治疗(每周1次),顺铂组放疗期间接受顺铂30 mg/m^(2)静脉注射治疗(每周1次),共5周。比较2组患者的有效率、疾病控制率、不良反应发生率和总生存期。结果2组有效率、疾病控制率比较,差异无统计学意义(P>0.05)。洛铂组恶心、呕吐发生率为40.0%(20/50),低于顺铂组的76.0%(38/50),差异有统计学意义(P<0.05);2组其他不良反应发生率比较,差异无统计学意义(P>0.05)。结论洛铂是一种较顺铂安全有效的同步化疗药物,可为局部晚期宫颈癌患者提供一种新的化疗策略。

Objective To compare efficacy and safety of lobaplatin combined with radiotherapy versus cisplatin plus radiotherapy for locally advanced cervical cancer.Methods A total of 100 cervical cancer patients in stageⅡB by International Federation of Gynecology and Obstetrics(FIGO)were randomized into lobaplatin group and cisplatin group,with 50 patients in each group.Patients in the lobaplatin group were administered lobaplatin intravenously for 10 mg/m^(2) once a week during radiotherapy,while patients in the cisplatin group were administered cisplatin intravenously for 30 mg/m^(2) once a week during radiotherapy,both group was treated for five cycles.The effective rates,disease control rates,incidence rates of adverse events and overall survival rates were compared between the two groups.Results Effective rates and disease control rates showed no statistically significant differences between the two groups(P>0.05).The incidence rates of nausea and vomiting were40.0%(20/50)in the lobaplatin group,which was siginificantly lower than 76.0%(38/50)in the cisplatin group(P<0.05);the incidence rates of other adverse events between the two groups showed no statistically significant differences(P>0.05).Conclusion Lobaplatin is a more effective and safe agent for locally advanced cervical cancer treatment than cisplatin,which can provide a novel strategy for patients with locally advanced cervical cancer.